Anti-VEGF Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global Anti-Vascular Endothelial Growth Factor (VEGF) market is on an upward trajectory, with a significant surge in value from US$ 24 billion in 2024 to a projected US$ 32 billion by the end of 2031. Anti-VEGF therapies, also known as VEGF inhibitors, have garnered increasing attention as a vital component in the treatment of various cancers. These inhibitors disrupt the activity of VEGF, a protein responsible for blood vessel growth, ultimately impeding the nutrient and oxygen supply to cancer cells, leading to their demise.
Key Factors Driving the Sales of VEGF Inhibitors
• Increasing Regulatory Approvals Validating Use: VEGF inhibitor manufacturers are securing regulatory approvals, ensuring the safety and efficacy of their products. New approvals are set to drive product sales and offer opportunities for diverse and innovative product portfolios.
• Advancements in Ocular Drug Delivery: Innovations like dendrimer-encapsulated drug molecules, enabling controlled release in the intraocular space, and liposome intravitreal injections for retinal disorders are expected to boost demand for VEGF inhibitors.
Challenges in Demand Growth for VEGF Inhibitors
• Adverse Effects: While VEGF inhibitors have shown clinical benefits in cancer treatment, they come with associated adverse effects, including bleeding and an increased risk of thrombosis, which pose challenges in patient management.
Country-wise Insights
• United States - A Lucrative Market: The United States has emerged as a thriving market for VEGF inhibitors, driven by the rising prevalence of cancer and patients' access to advanced treatment options. The country's well-developed healthcare system ensures that patients receive the best available care, including VEGF inhibitors.
• China - Government Funding Boosts Demand: China's aging population has led to a surge in cancer cases, making it a prominent market for VEGF inhibitors. Increasing government funding for healthcare systems is further boosting the demand for these drugs.
• Australia - Utilization of Combination Therapies: Australia, with its strong healthcare system and high cancer incidence rates, is witnessing increased utilization of combination therapies involving VEGF inhibitors for cancer treatment. Improved patient outcomes are driving demand in this market.
Competitive Landscape
The competitive landscape of the Anti-VEGF market is dynamic, with leading companies such as Pfizer Inc., Novartis AG, Sanofi SA, and others prioritizing licensing agreements and expanding their product portfolios to maintain their market positions. The constant innovation and endorsement of novel drugs for various cancer categories are shaping the market's competitive dynamics.
• Pfizer Inc.
• Novartis AG
• Sanofi SA
• Bayer Healthcare LLC
• F. Hoffmann-La Roche Ltd.
• Amgen Inc.
• Eli Lilly and Company
• Eisai Co., Ltd.
• Sino Pharma
• Amneal Pharmaceuticals Inc.
• Exelixis, Inc.
• HUTCHMED
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Takeda Pharmaceutical Company Limited
Key Segments of Anti-VEGF Industry Research
By Drug:
• Small Molecules
Pazopanib
Sunitinib
Sorafenib
Regorafenib
Cabozantinib
Lenvatinib
Ponatinib
Cabozantinib
Axitinib
Tivozanib
Vandetanib
Anlotinib
Apatinib
Fruquintinib
Surufatinib
• Biologics
Bevacizumab
Aflibercept
Ramucirumab
By Type:
• VEGF-A Inhibitors
• VEGF-B Inhibitors
• VEGF-C Inhibitors
• Placenta Growth Factor Inhibitors
By Disease Indication:
• Oncology
Non-Small Cell Lung Cancer
Renal Cell Carcinoma
Colorectal Cancer
Hepatocellular Carcinoma
Cervical Cancer
Others
• Hematology Disorders
• Ophthalmology Disorders
Wet Age-related Macular Degeneration (AMD)
Diabetic Retinopathy
Others
By Distribution Channel:
• Hospitals
• Specialty Clinics
• Mail Order Pharmacies
Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa
Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.
- 1. Executive Summary
- 1.1. Global Anti-VEGF Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2023
- 1.5. Analyst Recommendations
- 2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. Porter’s Five Forces Analysis
- 2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
- 2.6. Impact of Ukraine-Russia Conflict
- 2.7. Economic Overview
- 2.7.1. World Economic Projections
- 2.8. PESTLE Analysis
- 3. Global Anti-VEGF Market Outlook, 2018 – 2031
- 3.1. Global Anti-VEGF Market Outlook, by Drug, Value (US$ Bn), 2018 – 2031
- 3.1.1. Key Highlights
- 3.1.1.1. Small Molecules
- 3.1.1.1.1. Pazopanib
- 3.1.1.1.2. Sunitinib
- 3.1.1.1.3. Sorafenib
- 3.1.1.1.4. Regorafenib
- 3.1.1.1.5. Cabozantinib
- 3.1.1.1.6. Lenvatinib
- 3.1.1.1.7. Ponatinib
- 3.1.1.1.8. Cabozantinib
- 3.1.1.1.9. Axitinib
- 3.1.1.1.10. Tivozanib
- 3.1.1.1.11. Vandetanib
- 3.1.1.1.12. Anlotinib
- 3.1.1.1.13. Apatinib
- 3.1.1.1.14. Fruquintinib
- 3.1.1.1.15. Surufatinib
- 3.1.1.2. Biologics
- 3.1.1.2.1. Bevacizumab
- 3.1.1.2.2. Aflibercept
- 3.1.1.2.3. Ramucirumab
- 3.2. Global Anti-VEGF Market Outlook, by Type, Value (US$ Bn), 2018 – 2031
- 3.2.1. Key Highlights
- 3.2.1.1. VEGF-A Inhibitors
- 3.2.1.2. VEGF-B Inhibitors
- 3.2.1.3. VEGF-C Inhibitors
- 3.2.1.4. Placenta Growth Factor Inhibitors
- 3.3. Global Anti-VEGF Market Outlook, By Disease Indication, Value (US$ Bn), 2018 – 2031
- 3.3.1. Key Highlights
- 3.3.1.1. Oncology
- 3.3.1.1.1. Non-Small Cell Lung Cancer
- 3.3.1.1.2. Renal Cell Carcinoma
- 3.3.1.1.3. Colorectal Cancer
- 3.3.1.1.4. Hepatocellular Carcinoma
- 3.3.1.1.5. Cervical Cancer
- 3.3.1.1.6. Others
- 3.3.1.2. Hematology Disorders
- 3.3.1.3. Ophthalmology Disorders
- 3.3.1.3.1. Wet Age-related Macular Degeneration (AMD)
- 3.3.1.3.2. Diabetic Retinopathy
- 3.3.1.3.3. Others
- 3.4. Global Anti-VEGF Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 – 2031
- 3.4.1. Key Highlights
- 3.4.1.1. Hospitals
- 3.4.1.2. Specialty Clinics
- 3.4.1.3. Mail Order Pharmacies
- 3.5. Global Anti-VEGF Market Outlook, by Region, Value (US$ Bn), 2018 – 2031
- 3.5.1. Key Highlights
- 3.5.1.1. North America
- 3.5.1.2. Europe
- 3.5.1.3. Asia Pacific
- 3.5.1.4. Latin America
- 3.5.1.5. Middle East & Africa
- 4. North America Anti-VEGF Market Outlook, 2018 – 2031
- 4.1. North America Anti-VEGF Market Outlook, by Drug, Value (US$ Bn), 2018 – 2031
- 4.1.1. Key Highlights
- 4.1.1.1. Small Molecules
- 4.1.1.1.1. Pazopanib
- 4.1.1.1.2. Sunitinib
- 4.1.1.1.3. Sorafenib
- 4.1.1.1.4. Regorafenib
- 4.1.1.1.5. Cabozantinib
- 4.1.1.1.6. Lenvatinib
- 4.1.1.1.7. Ponatinib
- 4.1.1.1.8. Cabozantinib
- 4.1.1.1.9. Axitinib
- 4.1.1.1.10. Tivozanib
- 4.1.1.1.11. Vandetanib
- 4.1.1.1.12. Anlotinib
- 4.1.1.1.13. Apatinib
- 4.1.1.1.14. Fruquintinib
- 4.1.1.1.15. Surufatinib
- 4.1.1.2. Biologics
- 4.1.1.2.1. Bevacizumab
- 4.1.1.2.2. Aflibercept
- 4.1.1.2.3. Ramucirumab
- 4.2. North America Anti-VEGF Market Outlook, by Type, Value (US$ Bn), 2018 – 2031
- 4.2.1. Key Highlights
- 4.2.1.1. VEGF-A Inhibitors
- 4.2.1.2. VEGF-B Inhibitors
- 4.2.1.3. VEGF-C Inhibitors
- 4.2.1.4. Placenta Growth Factor Inhibitors
- 4.3. North America Anti-VEGF Market Outlook, By Disease Indication, Value (US$ Bn), 2018 – 2031
- 4.3.1. Key Highlights
- 4.3.1.1. Oncology
- 4.3.1.1.1. Non-Small Cell Lung Cancer
- 4.3.1.1.2. Renal Cell Carcinoma
- 4.3.1.1.3. Colorectal Cancer
- 4.3.1.1.4. Hepatocellular Carcinoma
- 4.3.1.1.5. Cervical Cancer
- 4.3.1.1.6. Others
- 4.3.1.2. Hematology Disorders
- 4.3.1.3. Ophthalmology Disorders
- 4.3.1.3.1. Wet Age-related Macular Degeneration (AMD)
- 4.3.1.3.2. Diabetic Retinopathy
- 4.3.1.3.3. Others
- 4.4. North America Anti-VEGF Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 – 2031
- 4.4.1. Key Highlights
- 4.4.1.1. Hospitals
- 4.4.1.2. Specialty Clinics
- 4.4.1.3. Mail Order Pharmacies
- 4.5. North America Anti-VEGF Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 4.5.1. Key Highlights
- 4.5.1.1. U.S. Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 4.5.1.2. U.S. Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 4.5.1.3. U.S. Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 4.5.1.4. U.S. Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 4.5.1.5. Canada Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 4.5.1.6. Canada Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 4.5.1.7. Canada Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 4.5.1.8. Canada Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 4.5.2. BPS Analysis/Market Attractiveness Analysis
- 5. Europe Anti-VEGF Market Outlook, 2018 – 2031
- 5.1. Europe Anti-VEGF Market Outlook, by Drug, Value (US$ Bn), 2018 – 2031
- 5.1.1. Key Highlights
- 5.1.1.1. Small Molecules
- 5.1.1.1.1. Pazopanib
- 5.1.1.1.2. Sunitinib
- 5.1.1.1.3. Sorafenib
- 5.1.1.1.4. Regorafenib
- 5.1.1.1.5. Cabozantinib
- 5.1.1.1.6. Lenvatinib
- 5.1.1.1.7. Ponatinib
- 5.1.1.1.8. Cabozantinib
- 5.1.1.1.9. Axitinib
- 5.1.1.1.10. Tivozanib
- 5.1.1.1.11. Vandetanib
- 5.1.1.1.12. Anlotinib
- 5.1.1.1.13. Apatinib
- 5.1.1.1.14. Fruquintinib
- 5.1.1.1.15. Surufatinib
- 5.1.1.2. Biologics
- 5.1.1.2.1. Bevacizumab
- 5.1.1.2.2. Aflibercept
- 5.1.1.2.3. Ramucirumab
- 5.2. Europe Anti-VEGF Market Outlook, by Type, Value (US$ Bn), 2018 – 2031
- 5.2.1. Key Highlights
- 5.2.1.1. VEGF-A Inhibitors
- 5.2.1.2. VEGF-B Inhibitors
- 5.2.1.3. VEGF-C Inhibitors
- 5.2.1.4. Placenta Growth Factor Inhibitors
- 5.3. Europe Anti-VEGF Market Outlook, By Disease Indication, Value (US$ Bn), 2018 – 2031
- 5.3.1. Key Highlights
- 5.3.1.1. Oncology
- 5.3.1.1.1. Non-Small Cell Lung Cancer
- 5.3.1.1.2. Renal Cell Carcinoma
- 5.3.1.1.3. Colorectal Cancer
- 5.3.1.1.4. Hepatocellular Carcinoma
- 5.3.1.1.5. Cervical Cancer
- 5.3.1.1.6. Others
- 5.3.1.2. Hematology Disorders
- 5.3.1.3. Ophthalmology Disorders
- 5.3.1.3.1. Wet Age-related Macular Degeneration (AMD)
- 5.3.1.3.2. Diabetic Retinopathy
- 5.3.1.3.3. Others
- 5.4. Europe Anti-VEGF Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.1. Key Highlights
- 5.4.1.1. Hospitals
- 5.4.1.2. Specialty Clinics
- 5.4.1.3. Mail Order Pharmacies
- 5.5. Europe Anti-VEGF Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 5.5.1. Key Highlights
- 5.5.1.1. Germany Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 5.5.1.2. Germany Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 5.5.1.3. Germany Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 5.5.1.4. Germany Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.5.1.5. U.K. Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 5.5.1.6. U.K. Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 5.5.1.7. U.K. Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 5.5.1.8. U.K. Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.5.1.9. France Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 5.5.1.10. France Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 5.5.1.11. France Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 5.5.1.12. France Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.5.1.13. Italy Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 5.5.1.14. Italy Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 5.5.1.15. Italy Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 5.5.1.16. Italy Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.5.1.17. Turkey Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 5.5.1.18. Turkey Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 5.5.1.19. Turkey Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 5.5.1.20. Turkey Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.5.1.21. Russia Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 5.5.1.22. Russia Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 5.5.1.23. Russia Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 5.5.1.24. Russia Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.5.1.25. Rest of Europe Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 5.5.1.26. Rest of Europe Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 5.5.1.27. Rest of Europe Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 5.5.1.28. Rest of Europe Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.5.2. BPS Analysis/Market Attractiveness Analysis
- 6. Asia Pacific Anti-VEGF Market Outlook, 2018 – 2031
- 6.1. Asia Pacific Anti-VEGF Market Outlook, by Drug, Value (US$ Bn), 2018 – 2031
- 6.1.1. Key Highlights
- 6.1.1.1. Small Molecules
- 6.1.1.1.1. Pazopanib
- 6.1.1.1.2. Sunitinib
- 6.1.1.1.3. Sorafenib
- 6.1.1.1.4. Regorafenib
- 6.1.1.1.5. Cabozantinib
- 6.1.1.1.6. Lenvatinib
- 6.1.1.1.7. Ponatinib
- 6.1.1.1.8. Cabozantinib
- 6.1.1.1.9. Axitinib
- 6.1.1.1.10. Tivozanib
- 6.1.1.1.11. Vandetanib
- 6.1.1.1.12. Anlotinib
- 6.1.1.1.13. Apatinib
- 6.1.1.1.14. Fruquintinib
- 6.1.1.1.15. Surufatinib
- 6.1.1.2. Biologics
- 6.1.1.2.1. Bevacizumab
- 6.1.1.2.2. Aflibercept
- 6.1.1.2.3. Ramucirumab
- 6.2. Asia Pacific Anti-VEGF Market Outlook, by Type, Value (US$ Bn), 2018 – 2031
- 6.2.1. Key Highlights
- 6.2.1.1. VEGF-A Inhibitors
- 6.2.1.2. VEGF-B Inhibitors
- 6.2.1.3. VEGF-C Inhibitors
- 6.2.1.4. Placenta Growth Factor Inhibitors
- 6.3. Asia Pacific Anti-VEGF Market Outlook, By Disease Indication, Value (US$ Bn), 2018 – 2031
- 6.3.1. Key Highlights
- 6.3.1.1. Oncology
- 6.3.1.1.1. Non-Small Cell Lung Cancer
- 6.3.1.1.2. Renal Cell Carcinoma
- 6.3.1.1.3. Colorectal Cancer
- 6.3.1.1.4. Hepatocellular Carcinoma
- 6.3.1.1.5. Cervical Cancer
- 6.3.1.1.6. Others
- 6.3.1.2. Hematology Disorders
- 6.3.1.3. Ophthalmology Disorders
- 6.3.1.3.1. Wet Age-related Macular Degeneration (AMD)
- 6.3.1.3.2. Diabetic Retinopathy
- 6.3.1.3.3. Others
- 6.4. Asia Pacific Anti-VEGF Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.4.1. Key Highlights
- 6.4.1.1. Hospitals
- 6.4.1.2. Specialty Clinics
- 6.4.1.3. Mail Order Pharmacies
- 6.5. Asia Pacific Anti-VEGF Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 6.5.1. Key Highlights
- 6.5.1.1. China Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 6.5.1.2. China Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 6.5.1.3. China Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 6.5.1.4. China Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.5.1.5. Japan Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 6.5.1.6. Japan Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 6.5.1.7. Japan Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 6.5.1.8. Japan Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.5.1.9. South Korea Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 6.5.1.10. South Korea Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 6.5.1.11. South Korea Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 6.5.1.12. South Korea Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.5.1.13. India Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 6.5.1.14. India Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 6.5.1.15. India Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 6.5.1.16. India Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.5.1.17. Southeast Asia Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 6.5.1.18. Southeast Asia Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 6.5.1.19. Southeast Asia Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 6.5.1.20. Southeast Asia Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.5.1.21. Rest of Asia Pacific Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 6.5.1.22. Rest of Asia Pacific Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 6.5.1.23. Rest of Asia Pacific Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 6.5.1.24. Rest of Asia Pacific Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.5.2. BPS Analysis/Market Attractiveness Analysis
- 7. Latin America Anti-VEGF Market Outlook, 2018 – 2031
- 7.1. Latin America Anti-VEGF Market Outlook, by Drug, Value (US$ Bn), 2018 – 2031
- 7.1.1. Key Highlights
- 7.1.1.1. Small Molecules
- 7.1.1.1.1. Pazopanib
- 7.1.1.1.2. Sunitinib
- 7.1.1.1.3. Sorafenib
- 7.1.1.1.4. Regorafenib
- 7.1.1.1.5. Cabozantinib
- 7.1.1.1.6. Lenvatinib
- 7.1.1.1.7. Ponatinib
- 7.1.1.1.8. Cabozantinib
- 7.1.1.1.9. Axitinib
- 7.1.1.1.10. Tivozanib
- 7.1.1.1.11. Vandetanib
- 7.1.1.1.12. Anlotinib
- 7.1.1.1.13. Apatinib
- 7.1.1.1.14. Fruquintinib
- 7.1.1.1.15. Surufatinib
- 7.1.1.2. Biologics
- 7.1.1.2.1. Bevacizumab
- 7.1.1.2.2. Aflibercept
- 7.1.1.2.3. Ramucirumab
- 7.2. Latin America Anti-VEGF Market Outlook, by Type, Value (US$ Bn), 2018 – 2031
- 7.2.1.1. VEGF-A Inhibitors
- 7.2.1.2. VEGF-B Inhibitors
- 7.2.1.3. VEGF-C Inhibitors
- 7.2.1.4. Placenta Growth Factor Inhibitors
- 7.3. Latin America Anti-VEGF Market Outlook, By Disease Indication, Value (US$ Bn), 2018 – 2031
- 7.3.1. Key Highlights
- 7.3.1.1. Oncology
- 7.3.1.1.1. Non-Small Cell Lung Cancer
- 7.3.1.1.2. Renal Cell Carcinoma
- 7.3.1.1.3. Colorectal Cancer
- 7.3.1.1.4. Hepatocellular Carcinoma
- 7.3.1.1.5. Cervical Cancer
- 7.3.1.1.6. Others
- 7.3.1.2. Hematology Disorders
- 7.3.1.3. Ophthalmology Disorders
- 7.3.1.3.1. Wet Age-related Macular Degeneration (AMD)
- 7.3.1.3.2. Diabetic Retinopathy
- 7.3.1.3.3. Others
- 7.4. Latin America Anti-VEGF Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.4.1. Key Highlights
- 7.4.1.1. Hospitals
- 7.4.1.2. Specialty Clinics
- 7.4.1.3. Mail Order Pharmacies
- 7.5. Latin America Anti-VEGF Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 7.5.1. Key Highlights
- 7.5.1.1. Brazil Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 7.5.1.2. Brazil Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 7.5.1.3. Brazil Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 7.5.1.4. Brazil Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.5.1.5. Mexico Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 7.5.1.6. Mexico Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 7.5.1.7. Mexico Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 7.5.1.8. Mexico Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.5.1.9. Argentina Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 7.5.1.10. Argentina Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 7.5.1.11. Argentina Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 7.5.1.12. Argentina Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.5.1.13. Rest of Latin America Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 7.5.1.14. Rest of Latin America Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 7.5.1.15. Rest of Latin America Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 7.5.1.16. Rest of Latin America Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.5.2. BPS Analysis/Market Attractiveness Analysis
- 8. Middle East & Africa Anti-VEGF Market Outlook, 2018 – 2031
- 8.1. Middle East & Africa Anti-VEGF Market Outlook, by Drug, Value (US$ Bn), 2018 – 2031
- 8.1.1. Key Highlights
- 8.1.1.1. Small Molecules
- 8.1.1.1.1. Pazopanib
- 8.1.1.1.2. Sunitinib
- 8.1.1.1.3. Sorafenib
- 8.1.1.1.4. Regorafenib
- 8.1.1.1.5. Cabozantinib
- 8.1.1.1.6. Lenvatinib
- 8.1.1.1.7. Ponatinib
- 8.1.1.1.8. Cabozantinib
- 8.1.1.1.9. Axitinib
- 8.1.1.1.10. Tivozanib
- 8.1.1.1.11. Vandetanib
- 8.1.1.1.12. Anlotinib
- 8.1.1.1.13. Apatinib
- 8.1.1.1.14. Fruquintinib
- 8.1.1.1.15. Surufatinib
- 8.1.1.2. Biologics
- 8.1.1.2.1. Bevacizumab
- 8.1.1.2.2. Aflibercept
- 8.1.1.2.3. Ramucirumab
- 8.2. Middle East & Africa Anti-VEGF Market Outlook, by Type, Value (US$ Bn), 2018 – 2031
- 8.2.1. Key Highlights
- 8.2.1.1. VEGF-A Inhibitors
- 8.2.1.2. VEGF-B Inhibitors
- 8.2.1.3. VEGF-C Inhibitors
- 8.2.1.4. Placenta Growth Factor Inhibitors
- 8.3. Middle East & Africa Anti-VEGF Market Outlook, By Disease Indication, Value (US$ Bn), 2018 – 2031
- 8.3.1. Key Highlights
- 8.3.1.1. Oncology
- 8.3.1.1.1. Non-Small Cell Lung Cancer
- 8.3.1.1.2. Renal Cell Carcinoma
- 8.3.1.1.3. Colorectal Cancer
- 8.3.1.1.4. Hepatocellular Carcinoma
- 8.3.1.1.5. Cervical Cancer
- 8.3.1.1.6. Others
- 8.3.1.2. Hematology Disorders
- 8.3.1.3. Ophthalmology Disorders
- 8.3.1.3.1. Wet Age-related Macular Degeneration (AMD)
- 8.3.1.3.2. Diabetic Retinopathy
- 8.3.1.3.3. Others
- 8.4. Middle East & Africa Anti-VEGF Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.4.1. Key Highlights
- 8.4.1.1. Hospitals
- 8.4.1.2. Specialty Clinics
- 8.4.1.3. Mail Order Pharmacies
- 8.5. Middle East & Africa Anti-VEGF Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 8.5.1. Key Highlights
- 8.5.1.1. GCC Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 8.5.1.2. GCC Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 8.5.1.3. GCC Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 8.5.1.4. GCC Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.5.1.5. South Africa Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 8.5.1.6. South Africa Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 8.5.1.7. South Africa Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 8.5.1.8. South Africa Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.5.1.9. Egypt Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 8.5.1.10. Egypt Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 8.5.1.11. Egypt Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 8.5.1.12. Egypt Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.5.1.13. Nigeria Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 8.5.1.14. Nigeria Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 8.5.1.15. Nigeria Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 8.5.1.16. Nigeria Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.5.1.17. Rest of Middle East & Africa Anti-VEGF Market by Drug, Value (US$ Bn), 2018 – 2031
- 8.5.1.18. Rest of Middle East & Africa Anti-VEGF Market by Type, Value (US$ Bn), 2018 – 2031
- 8.5.1.19. Rest of Middle East & Africa Anti-VEGF Market by Disease Indication, Value (US$ Bn), 2018 – 2031
- 8.5.1.20. Rest of Middle East & Africa Anti-VEGF Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.5.2. BPS Analysis/Market Attractiveness Analysis
- 9. Competitive Landscape
- 9.1. Type vs Drug Heatmap
- 9.2. Company Market Share Analysis, 2023
- 9.3. Competitive Dashboard
- 9.4. Company Profiles
- 9.4.1. Pfizer Inc.
- 9.4.1.1. Company Overview
- 9.4.1.2. Product Portfolio
- 9.4.1.3. Financial Overview
- 9.4.1.4. Business Strategies and Development
- 9.4.2. Novartis AG
- 9.4.2.1. Company Overview
- 9.4.2.2. Product Portfolio
- 9.4.2.3. Financial Overview
- 9.4.2.4. Business Strategies and Development
- 9.4.3. Sanofi SA
- 9.4.3.1. Company Overview
- 9.4.3.2. Product Portfolio
- 9.4.3.3. Financial Overview
- 9.4.3.4. Business Strategies and Development
- 9.4.4. Bayer Healthcare LLC
- 9.4.4.1. Company Overview
- 9.4.4.2. Product Portfolio
- 9.4.4.3. Financial Overview
- 9.4.4.4. Business Strategies and Development
- 9.4.5. F. Hoffmann-La Roche Ltd.
- 9.4.5.1. Company Overview
- 9.4.5.2. Product Portfolio
- 9.4.5.3. Financial Overview
- 9.4.5.4. Business Strategies and Development
- 9.4.6. Amgen Inc.
- 9.4.6.1. Company Overview
- 9.4.6.2. Product Portfolio
- 9.4.6.3. Financial Overview
- 9.4.6.4. Business Strategies and Development
- 9.4.7. Eli Lilly and Company
- 9.4.7.1. Company Overview
- 9.4.7.2. Product Portfolio
- 9.4.7.3. Financial Overview
- 9.4.7.4. Business Strategies and Development
- 9.4.8. Eisai Co., Ltd.
- 9.4.8.1. Company Overview
- 9.4.8.2. Product Portfolio
- 9.4.8.3. Financial Overview
- 9.4.8.4. Business Strategies and Development
- 9.4.9. Sino Pharma
- 9.4.9.1. Company Overview
- 9.4.9.2. Product Portfolio
- 9.4.9.3. Financial Overview
- 9.4.9.4. Business Strategies and Development
- 9.4.10. Amneal Pharmaceuticals Inc.
- 9.4.10.1. Company Overview
- 9.4.10.2. Product Portfolio
- 9.4.10.3. Financial Overview
- 9.4.10.4. Business Strategies and Development
- 9.4.11. Exelixis, Inc.
- 9.4.11.1. Company Overview
- 9.4.11.2. Product Portfolio
- 9.4.11.3. Financial Overview
- 9.4.11.4. Business Strategies and Development
- 9.4.12. HUTCHMED
- 9.4.12.1. Company Overview
- 9.4.12.2. Product Portfolio
- 9.4.12.3. Financial Overview
- 9.4.12.4. Business Strategies and Development
- 9.4.13. Takeda Pharmaceutical Company Limited
- 9.4.13.1. Company Overview
- 9.4.13.2. Product Portfolio
- 9.4.13.3. Financial Overview
- 9.4.13.4. Business Strategies and Development
- 10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook